INDIANAPOLIS— The makers of a popular antibiotic have halted production on the drug amid safety concerns.
Janssen pharmaceutical companies of Johnson & Johnson discontinued production of Levaquin in December 2017, including the oral and IV versions.
However, Levaquin may still be available in pharmacies until 2020.
“The decision to discontinue LEVAQUIN was made due to the wide availability of alternative treatment options, and our focus on developing innovative medicines designed to address unmet medical patient needs,” said Kelsey Buckholtz, a spokeswoman for Janssen in an email to RTV6.
The new labels will include more prominent and consistent warnings for mental health side effects.
A Janssen spokeswoman said Tuesday the company also discontinued making Floxin Otic ear drops, which is also a fluoroquinolone.
For several years, Call 6 Investigates has been looking into potential safety issues and concerning side effects associated with fluoroquinolone antibiotics including psychiatric problems, tendon rupture and nerve damage.
Purdue University student Shea McCarty died in 2013 after jumping out of a second story window and crashing his car into a cement embankment.
His mother, Heather McCarthy, said Shea was agitated and suffering mental health side effects from taking the antibiotic Levaquin.
Dr. Charles Bennett with the Southern Network on Adverse Reactions (SONAR) said Tuesday that Janssen’s decision will have little impact on public safety because other drug makers are still making the generic form, known as levofloxacin.
“Levaquin was only about 1 percent of the market share, and 99 percent was the generic,” said Bennett. “It was hard for them to make money given the lawsuits they were facing.”
Heather McCarthy told Call 6 Investigates Monday the FDA’s announcement is a breakthrough in acknowledging the drugs’ effects.
“While justice is slow - this label will now open the doors to accountability for doctors who chose to ignore patient complaints,” McCarthy said in an email to RTV6 Monday. “I personally believe there is a never a reason for doctors not to listen to patients and with this labeling, there is no longer a viable excuse to ignore patient complaints associated with fluoroquinolones. The key here is ending the degradation that patients must go through when they believe they have had an adverse effect from these drugs.”
Dr. Bennett called the FDA’s July 10 announcement a “huge paradigm shift.”
In 2016, the FDA announced an updated boxed warning and medication guide that advised serious side effects with fluoroquinolones generally outweigh the benefits for patients with sinusitis, bronchitis and uncomplicated urinary tract infections who have other treatment options.
Patients with those conditions should only use fluoroquinolones as a last resort, according to the FDA.
Fluoroquinolones are intended to treat major infections like pneumonia, anthrax exposure, plague and urinary tract infections.
Call 6 Investigates contacted Janssen, the maker of Levaquin, about the FDA’s July 10 announcement.
“At Janssen, our first priority is the well-being of the people who use our medicines. Janssen is reviewing the Safety Labeling Change Notification and working with the FDA to ensure labeling will be updated appropriately to facilitate the safe and appropriate use of LEVAQUIN®,” said Kelsey Buckholtz, Janssen spokesperson in a statement to RTV6. “LEVAQUIN® (levofloxacin) has been used for nearly 20 years to treat bacterial infections, including those that may be serious or life-threatening. LEVAQUIN® is part of the important fluoroquinolone class of anti-infective prescription medications, and its safety profile remains well-known and established.”
Call 6 Investigates also contacted Bayer, who makes Cipro and Avelox, about the FDA’s label change.
Bayer released the following statement:
“Fluoroquinolones, including Cipro® (ciprofloxacin) and Avelox® (moxifloxacin), are an important class of antibiotics that treat a range of bacterial infections, some of which are serious and can be life-threatening. Cipro has been used in more than 600 million patients worldwide since becoming available by prescription in 1987. Avelox has been used by more than 200 million patients since it became available in 1999.
FDA, on July 10, 2018, issued an announcement [fda.gov] to reinforce safety information about the risks of low blood sugar levels and mental health side effects with fluoroquinolone antibiotics, and is requiring label changes for these products. This is a class-wide labeling change for all NDA and ANDA holders of fluoroquinolone antibiotics. Companies have 30 days to respond to the proposed label changes. Bayer is currently reviewing the proposed Labeling Change Notifications for Cipro and Avelox, and we will respond to the agency within the required time frame.
The current approved product labeling of both Cipro and Avelox reflects the benefit-risk profile of these drugs in their approved indications, including information about the risks of mental health side effects and hypoglycemia (low blood sugar).
Bayer’s highest priority is patient safety and we closely monitor the safety and efficacy of Cipro and Avelox on an ongoing basis. Bayer takes all reports of side effects very seriously, investigates them thoroughly, reports them to health authorities around the world as required and regularly evaluates whether the product’s benefit risk profile is adequately reflected in the product information.”